JP2011516427A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516427A5 JP2011516427A5 JP2011502132A JP2011502132A JP2011516427A5 JP 2011516427 A5 JP2011516427 A5 JP 2011516427A5 JP 2011502132 A JP2011502132 A JP 2011502132A JP 2011502132 A JP2011502132 A JP 2011502132A JP 2011516427 A5 JP2011516427 A5 JP 2011516427A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- optionally substituted
- heterocyclyl
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 125000004452 carbocyclyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000002947 alkylene group Chemical group 0.000 claims 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 8
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- -1 hydroxy, amino Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010060971 Astrocytoma malignant Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010054261 Flavivirus infection Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000004571 Pestivirus Infections Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 claims 1
- 208000030239 cerebral astrocytoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000030883 malignant astrocytoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4051608P | 2008-03-28 | 2008-03-28 | |
| US61/040,516 | 2008-03-28 | ||
| PCT/US2009/038805 WO2009121063A2 (en) | 2008-03-28 | 2009-03-30 | Chemokine receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516427A JP2011516427A (ja) | 2011-05-26 |
| JP2011516427A5 true JP2011516427A5 (enExample) | 2012-05-24 |
| JP5690715B2 JP5690715B2 (ja) | 2015-03-25 |
Family
ID=41114825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502132A Expired - Fee Related JP5690715B2 (ja) | 2008-03-28 | 2009-03-30 | ケモカイン受容体調節因子 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8338448B2 (enExample) |
| EP (2) | EP2664618A3 (enExample) |
| JP (1) | JP5690715B2 (enExample) |
| KR (1) | KR20110005819A (enExample) |
| CN (1) | CN102015717A (enExample) |
| AU (1) | AU2009228034A1 (enExample) |
| BR (1) | BRPI0909375A2 (enExample) |
| CA (1) | CA2718618A1 (enExample) |
| DK (1) | DK2262808T3 (enExample) |
| IL (1) | IL208185A0 (enExample) |
| MX (1) | MX2010010619A (enExample) |
| NZ (1) | NZ587929A (enExample) |
| SG (1) | SG189723A1 (enExample) |
| WO (1) | WO2009121063A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100518160B1 (ko) * | 1996-11-05 | 2006-09-18 | 닛폰 프라파렛트 가부시키가이샤 | 합성수지팔레트 |
| JP5690715B2 (ja) | 2008-03-28 | 2015-03-25 | アルテイリス・セラピユーテイクス | ケモカイン受容体調節因子 |
| WO2012075362A2 (en) | 2010-12-03 | 2012-06-07 | Emory University | Chemokine cxcr4 receptor modulators and used related thereto |
| CN105120863B (zh) * | 2013-03-14 | 2021-06-04 | 奥斯特克有限公司 | 促进骨生长的烷基胺骆驼蓬碱衍生物 |
| US10450293B2 (en) | 2014-05-16 | 2019-10-22 | Emory University | Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto |
| AU2015321654B2 (en) * | 2014-09-22 | 2019-10-31 | National Health Research Institutes | Heterocyclic compounds and use thereof |
| ES2907489T3 (es) | 2015-12-14 | 2022-04-25 | X4 Pharmaceuticals Inc | Métodos para el tratamiento del cáncer |
| US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2935834T3 (es) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Métodos para tratar enfermedad de inmunodeficiencia |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| EP3321264A1 (en) * | 2016-11-14 | 2018-05-16 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways |
| AU2018225556A1 (en) * | 2017-02-21 | 2019-10-03 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| US12384830B2 (en) | 2017-06-02 | 2025-08-12 | Regents Of The University Of Minnesota | Compositions and methods for improving immunotherapy |
| JP7282786B2 (ja) * | 2017-09-25 | 2023-05-29 | シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド | Ｃｘｃｒ４阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法 |
| WO2019060860A1 (en) * | 2017-09-25 | 2019-03-28 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | HETEROARYL COMPOUNDS AS INHIBITORS OF CXCR4, COMPOSITION AND METHOD OF USE THEREOF |
| CN109553604B (zh) * | 2017-09-25 | 2021-08-27 | 盛世泰科生物医药技术(苏州)有限公司 | 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用 |
| CN110669036B (zh) * | 2018-07-02 | 2022-02-11 | 盛世泰科生物医药技术(苏州)有限公司 | 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用 |
| WO2019183133A1 (en) | 2018-03-19 | 2019-09-26 | Emory University | Pan-Tropic Entry Inhibitors |
| ES3004565T3 (en) | 2018-08-14 | 2025-03-12 | Ossifi Therapeutics Llc | Pyrrolo - dipyridine compounds for the treatment of bone loss |
| CN113166058A (zh) | 2018-08-14 | 2021-07-23 | 奥斯特克有限公司 | 氟β-咔啉化合物 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2021183650A1 (en) | 2020-03-10 | 2021-09-16 | X4 Pharmaceuticals, Inc. | Methods for treating neutropenia |
| US20240293391A1 (en) * | 2021-06-24 | 2024-09-05 | Katholieke Universiteit Leuven | Isoquinoline and pyridine based cxcr4 antagonists |
| WO2024220485A2 (en) * | 2023-04-18 | 2024-10-24 | The Regents Of The University Of California | Dual inhibitors of dyrk1a and 5-ht2 for treating a brain disorder |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| US5631265A (en) * | 1994-03-11 | 1997-05-20 | Eli Lilly And Company | 8-substituted tetrahydro-beta-carbolines |
| US5993817A (en) * | 1995-01-23 | 1999-11-30 | Xenotech | Method to ameliorate osteolysis and metastasis |
| US6358915B1 (en) | 1995-03-07 | 2002-03-19 | George Washington University | Methods for inhibiting metastasis |
| WO1997000956A1 (en) | 1995-06-20 | 1997-01-09 | Trustees Of Boston University | Hypoxia-responsive adhesion molecules, specific antibodies, and their uses |
| US6344545B1 (en) | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
| US5922676A (en) | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
| AU1616499A (en) | 1997-12-01 | 1999-06-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chemokine variants and methods of use |
| JP2002506830A (ja) | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療的ケモカイン受容体アンタゴニスト |
| AU759144B2 (en) * | 1998-05-05 | 2003-04-03 | Adherex Technologies Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| AU1408300A (en) * | 1998-11-24 | 2000-06-13 | Hisamitsu Pharmaceutical Co. Inc. | Hiv infection inhibitors |
| US6750348B1 (en) * | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| AP1654A (en) | 1999-03-24 | 2006-09-01 | Anormed Inc | Chemokine receptor binding heterocyclic compounds. |
| EP2275447A1 (en) | 1999-11-24 | 2011-01-19 | Schering Corporation | Methods of inhibiting metastasis |
| US20030220482A1 (en) | 2000-02-03 | 2003-11-27 | Ziwei Huang | Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II |
| JP2003532683A (ja) | 2000-05-09 | 2003-11-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 造血細胞のｃｘｃｒ４アンタゴニスト治療 |
| DE60137435D1 (de) * | 2000-09-15 | 2009-03-05 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
| WO2002094261A1 (fr) | 2001-05-24 | 2002-11-28 | Kureha Chemical Industry Company, Limited | Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote |
| JPWO2003029218A1 (ja) | 2001-09-28 | 2005-01-13 | 呉羽化学工業株式会社 | 新規含窒素化合物及びその用途 |
| BRPI0215050B8 (pt) * | 2001-12-21 | 2021-05-25 | Anormed Inc | compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| ES2403932T3 (es) | 2002-08-27 | 2013-05-22 | Biokine Therapeutics Ltd. | Antagonista de CXCR4 y uso del mismo |
| DE10240064A1 (de) | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
| US20040132642A1 (en) * | 2002-11-12 | 2004-07-08 | Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services | Methods of inhibiting metastasis or growth of a tumor cell |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| EP1608318A4 (en) | 2003-03-27 | 2009-07-29 | Univ Emory | CXCR4 ANTAGONISTS AND METHOD OF USE |
| EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| EP1615633B1 (en) | 2003-04-22 | 2012-08-15 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2005048916A2 (en) * | 2003-11-20 | 2005-06-02 | Biovitrum Ab | Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders |
| MX2007008326A (es) * | 2005-01-07 | 2008-01-16 | Univ Emory | Antagonistas de cxcr4 para el tratamiento de una infeccion por vih. |
| CA2593578C (en) | 2005-01-07 | 2013-11-05 | Emory University | Cxcr4 antagonists for the treatment of medical disorders |
| WO2008008852A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
| US20080227799A1 (en) * | 2006-07-11 | 2008-09-18 | Liotta Dennis C | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders |
| US8080659B2 (en) * | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| WO2008112156A1 (en) | 2007-03-08 | 2008-09-18 | Altiris Therapeutics | Chemokine receptor modulators |
| WO2008109154A1 (en) | 2007-03-08 | 2008-09-12 | Altiris Therapeutics, Inc. | Chemokine receptor modulators |
| JP5690715B2 (ja) | 2008-03-28 | 2015-03-25 | アルテイリス・セラピユーテイクス | ケモカイン受容体調節因子 |
-
2009
- 2009-03-30 JP JP2011502132A patent/JP5690715B2/ja not_active Expired - Fee Related
- 2009-03-30 NZ NZ587929A patent/NZ587929A/xx not_active IP Right Cessation
- 2009-03-30 BR BRPI0909375-3A patent/BRPI0909375A2/pt not_active IP Right Cessation
- 2009-03-30 SG SG2013023692A patent/SG189723A1/en unknown
- 2009-03-30 EP EP13174241.3A patent/EP2664618A3/en not_active Withdrawn
- 2009-03-30 WO PCT/US2009/038805 patent/WO2009121063A2/en not_active Ceased
- 2009-03-30 MX MX2010010619A patent/MX2010010619A/es active IP Right Grant
- 2009-03-30 US US12/414,352 patent/US8338448B2/en not_active Expired - Fee Related
- 2009-03-30 AU AU2009228034A patent/AU2009228034A1/en not_active Abandoned
- 2009-03-30 EP EP09724705.0A patent/EP2262808B1/en not_active Not-in-force
- 2009-03-30 KR KR1020107023643A patent/KR20110005819A/ko not_active Ceased
- 2009-03-30 CA CA2718618A patent/CA2718618A1/en not_active Abandoned
- 2009-03-30 CN CN2009801150516A patent/CN102015717A/zh active Pending
- 2009-03-30 DK DK09724705.0T patent/DK2262808T3/da active
-
2010
- 2010-09-16 IL IL208185A patent/IL208185A0/en unknown
-
2012
- 2012-11-15 US US13/677,944 patent/US9314468B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516427A5 (enExample) | ||
| JP2025160318A5 (enExample) | ||
| RU2750727C9 (ru) | Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там | |
| ES2243441T3 (es) | Derivados de imidazolio fundidos. | |
| JP2013509431A5 (enExample) | ||
| GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| WO2006023460A3 (en) | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | |
| JP2011523412A5 (enExample) | ||
| WO2007146758A3 (en) | Novel mch receptor antagonists | |
| MY148487A (en) | Biphenyl derivatives | |
| JP2013522292A5 (enExample) | ||
| JP2011519941A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| JP2016505586A5 (enExample) | ||
| NZ590334A (en) | ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF | |
| ME02879B (me) | Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola | |
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| JP2010539110A5 (enExample) | ||
| JP2020504716A5 (enExample) | ||
| JP2011001339A5 (enExample) | ||
| MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
| JP2017526677A5 (enExample) | ||
| PL1735278T3 (pl) | Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne |